Table 1.
Clinical characteristics of type 1 diabetic patients before and after insulin and AHSCT treatments
| Insulin-only group | AHSCT group | |||
|---|---|---|---|---|
| Insulin-0M | Insulin-12M | AHSCT-0M | AHSCT-12M | |
| Age (years) | 20.18 ± 4.02 | 18.86 ± 1.46 | ||
| Gender (female/male) | 6/4 | 5/3 | ||
| BMI (kg/cm2) | 18.28 ± 1.39 | 19.25 ± 1.11 | ||
| FBG (mmol/L) | 6.50 ± 2.01 | 6.04 ± 1.70 | 6.26 ± 0.67 | 5.59 ± 1.40 |
| HbA1c (%) (mmol/mol)a |
12.20 ± 3.50 (109.90 ± 38.42) |
7.33 ± 1.42++
(56.63 ± 15.45) |
11.49 ± 1.46 (102.00 ± 16.06) |
6.80 ± 0.60###
(51.00 ± 6.73) |
| Anti-GAD (units/ml) | 1230.38 (669.43–1957.29) | 1200.00 (725.41–1980.02) | 943.68 (294.69–2085.04) | 150.4* (31.83–1315.52) |
| Insulin dose (U/kg/day) | 0.66 ± 0.30 | 0.52 ± 0.34 | 0.61 ± 0.27 | 0.15 ± 0.15**### |
| Fasting C-peptide (ng/ml) | 0.62 ± 0.25 | 0.60 ± 0.50 | 0.71 ± 0.30 | 1.01 ± 0.23*# |
| AUCC | 4.56 ± 2.50 | 4.76 ± 1.42 | 5.93 ± 2.54 | 9.59 ± 2.98**# |
Data presented as mean ± SD or median (95% CI)
AHSCT autologous hematopoietic stem cell transplantation, 0 M at baseline, 12 M at 12 months
# P < 0.05, ### P < 0.001, compared with the AHSCT-0M group
++ P < 0.01, compared with the Insulin-0M group
*P < 0.05, **P < 0.01, compared with the Insulin-12M group
aHbA1c values were calculated as mmol/mol. The NGSP converter is available online (http://www.ngsp.org/convert1.asp)